MYGN icon

Myriad Genetics

Positive
Neutral
Negative
Sentiment 3-Months
Positive
Neutral 65%
Negative

Neutral
GlobeNewsWire
yesterday
Myriad Genetics Adds F8, FXN Genes to Foresight Universal Plus Panel
The Foresight® Carrier Screen includes all conditions recommended by the American College of Medical Genetics and Genomics recommendations The Foresight® Carrier Screen includes all conditions recommended by the American College of Medical Genetics and Genomics recommendations
Myriad Genetics Adds F8, FXN Genes to Foresight Universal Plus Panel
Neutral
GlobeNewsWire
7 days ago
Breast Cancer Awareness Month: Patient and Clinician Share Insights on how to tackle the fear of cancer screenings on YourUpdateTV
Data Shows Misconceptions Fuel Cancer Fears but Genetic Testing Can Help New Myriad Genetics Cancer Risk Survey shows that more than half of women at high-risk for hereditary cancer would feel "empowered" by more advanced screening like genetic testing NEW YORK, Oct. 08, 2025 (GLOBE NEWSWIRE) -- A new nationwide survey from Myriad Genetics shows many women fear cancer screenings—yet most say genetic testing would actually give them peace of mind. During a recent satellite media tour in partnership with Myriad Genetics and D S Simon Media, OB-GYN Dr. Ifeyinwa Stitt and patient with hereditary cancer risk Jodi Lavery discussed how to overcome the fear of screenings, the importance of knowing your cancer family health history, and how genetic testing for hereditary cancer risk can empower women with knowledge that helps them take control of their health.
Breast Cancer Awareness Month: Patient and Clinician Share Insights on how to tackle the fear of cancer screenings on YourUpdateTV
Neutral
PRNewsWire
22 days ago
Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy
SALT LAKE CITY and BOSTON , Sept. 23, 2025 /PRNewswire/ -- Myriad Genetics (Nasdaq: MYGN), a leader in molecular diagnostic testing and precision medicine, and SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company transforming precision medicine, announced a strategic collaboration to develop and provide pharmaceutical companies with an innovative global liquid biopsy companion diagnostic (CDx) test.
Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy
Neutral
GlobeNewsWire
22 days ago
Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy
SALT LAKE CITY and BOSTON, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics (Nasdaq: MYGN), a leader in molecular diagnostic testing and precision medicine, and SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company transforming precision medicine, announced a strategic collaboration to develop and provide pharmaceutical companies with an innovative global liquid biopsy companion diagnostic (CDx) test.
Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy
Positive
Zacks Investment Research
29 days ago
Is it a Prudent Move to Retain MYGN Stock in Your Portfolio Now?
Myriad Genetics expands oncology testing and launches new diagnostics, but inflation and rising competition weigh on its outlook.
Is it a Prudent Move to Retain MYGN Stock in Your Portfolio Now?
Neutral
Seeking Alpha
1 month ago
Myriad Genetics, Inc. (MYGN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Myriad Genetics, Inc. (NASDAQ:MYGN ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 7:45 AM EDT Company Participants Samraat Raha - President, CEO & Director Ben Wheeler - Chief Financial Officer Conference Call Participants Yuko Oku - Morgan Stanley, Research Division Presentation Yuko Oku Equity Analyst Hi, everyone. My name is Yuko Oku, and I'm on the life science tools and diagnostics team here at Morgan Stanley.
Myriad Genetics, Inc. (MYGN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Positive
Zacks Investment Research
1 month ago
MYGN Stock Might Gain on The Lancet Study Backing Precise MRD
Myriad Genetics' Precise MRD study in The Lancet shows ctDNA detection power in oligometastatic ccRCC, supporting oncology growth plans.
MYGN Stock Might Gain on The Lancet Study Backing Precise MRD
Positive
Zacks Investment Research
1 month ago
MYGN's GeneSight Test Proven Superior to TAU: Stock to Gain?
Myriad Genetics' GeneSight test outperforms treatment-as-usual in major depression, raising hopes for broader adoption and renewed stock momentum.
MYGN's GeneSight Test Proven Superior to TAU: Stock to Gain?
Neutral
GlobeNewsWire
1 month ago
Myriad Genetics Announces Precise MRD Clinical Data Published in The Lancet Oncology
SALT LAKE CITY, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced The Lancet Oncology published a study highlighting the performance of Myriad's molecular residual disease (MRD) test, Precise® MRD, in patients with oligometastatic clear-cell renal cell carcinoma (ccRCC).
Myriad Genetics Announces Precise MRD Clinical Data Published in The Lancet Oncology
Neutral
GlobeNewsWire
1 month ago
New Meta-Analysis Demonstrates that Access to the GeneSight Test Can Significantly Improve Response and Remission Rates for Patients with Depression
SALT LAKE CITY, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced the publication of a new meta-analysis of six prospective controlled studies1 that included 3,532 adults with major depressive disorder (MDD).
New Meta-Analysis Demonstrates that Access to the GeneSight Test Can Significantly Improve Response and Remission Rates for Patients with Depression